Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 9 November 2017

PCI Biotech: Board of Directors update

PCI Biotech Holding    

Published: 08:00 CET 09-11-2017 /GlobeNewswire /Source: PCI Biotech Holding / : PCIB /ISIN: N00010405640

PCI Biotech: Board of Directors update

Prof. Kjetil Taskén, MD, PhD has notified PCI Biotech Holding ASA's Nomination Committee and Board of Directors that he is not able to be a candidate for re-election as Director of PCI Biotech Holding ASA's Board of Directors at the next ordinary general meeting, in May 2018. Prof. Taskén has recently been appointed Head of Institute for Cancer Research at Oslo University Hospital and is therefore not able to continue as a Director of PCI Biotech Holding ASA's Board of Directors. Prof. Taskén has served as a Director since October 2008.

"Professor Taskén's deep knowledge about immunology and cancer has been of immeasurable value to PCI Biotech.  We thank Kjetil for his many years of service on the Board of Directors and congratulate him on his new position", said Hans Peter Bøhn, the Chairman of the Board of Directors.

The Nomination Committee of PCI Biotech Holding ASA is responsible for submitting a recommendation to the General Meeting for the election of the Board of Directors. Jónas Einarsson is Chairman of the Nomination Committee of PCI Biotech Holding ASA.

Contact information:   
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway. www.pcibiotech.com      
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429.

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: PCI Biotech Holding ASA, Ullernchausséen 64, Oslo 0379, Norway
If you would like to unsubscribe and stop receiving these e-mails click here.